About NSG Ventures
NSG Ventures is a venture capital firm founded in 2020. It is primarily based out of Singapore, Singapore. As of May 2026, NSG Ventures is an active investor, having invested in 22 companies, with 1 new investment in the last 12 months. It primarily invests in Series A round in Singapore based startups. Its investments are spread across a wide range of sectors from Life Sciences to HealthTech and Enterprise Applications. Most recently it participated in the $***** Seed round of Protuoso Overall, NSG Ventures portfolio has seen 6 IPOs and 2 acquisitions including key companies like Nubank, Senti Bio and Foundation Medicine. A lot of funds co-invest with NSG Ventures, with names like Health Quest Capital sharing a substantial percentage of its portfolio. NSG Ventures has team of 7 people including 1 partners.Key Metrics
Team Members
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Seed & 1 more
Portfolio Acquisitions
Portfolio Soonicorns
NSG Ventures' List of Top Investments
NSG Ventures has a portfolio of 22 companies. Their most notable investments are in Sukhavati and Lunit.Their portfolio spans across United States, Singapore, Brazil and 3 more locations. They have invested in Life Sciences, HealthTech, Enterprise Applications and 11 other sectors, across stages such as Series A, Seed and 1 more. Here is the list of top investments by NSG Ventures:
1. Nubank
Provider of digital banking services, including credit cards and accounts. It offers various financial solutions through its application. These solutions include tools for managing money and protecting finances. The company focuses on providing accessible and straightforward banking experiences.
Key facts about Nubank
- Founded Year: 2013
- Location: Sao Paulo (Brazil)
- Annual Revenue: €1B+ as on Dec 31, 2024
- Stage: Public
- Total Funding till date: $2.27B
- Employee Count: 11,551 as on Mar 31, 2026
- Investors: Berkshire Hathaway, Harvest Growth Capital and 39 Others
- Latest Funding Round: Series G, Jun 08, 2021, $*****
- Highlight: Public
2. Senti Bio
Developer of cell and gene therapies for patients living with incurable diseases. The company has developed its proprietary synthetic biology platform to produce cell and gene therapies for cancer treatment. The company's pipeline is comprised of cell therapies engineered with Gene Circuits to target difficult to treat liquid and solid tumors. It offers CAR-NK-based therapies for multiple cancer and tumors.
Key facts about Senti Bio
- Founded Year: 2016
- Location: San Francisco (United States)
- Annual Revenue: $0 - $1M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $158M
- Employee Count: 65 as on Jun 30, 2026
- Investors: Allen & Company, Nantahala Capital Management and 30 Others
- Latest Funding Round: Post IPO, May 02, 2026, $*****
- Highlight: Public
3. ZUZU
Platform offering independent hotel management software and solutions. It features solutions for revenue management, booking management, channel management, property management, reputation management, analysis, and more. The platform combines real-time reporting with market intelligence solutions.
Key facts about ZUZU
- Founded Year: 2016
- Location: Singapore (Singapore)
- Annual Revenue: SGD 10M - 50M as on Dec 31, 2024
- Stage: Series B
- Total Funding till date: $21.6M
- Employee Count: 334 as on Jun 30, 2026
- Investors: Innoven Capital, SBVA and 24 Others
- Latest Funding Round: Series B, Aug 28, 2025, $*****
- Highlight: Editors' Pick
Provider of genomics-based diagnostics test for cancer. The company's clinical assays, FoundationOne for solid tumors, FoundationOne Heme for hematologic malignancies and sarcomas, and the liquid biopsy test FoundationACT provide a complete genomic profile of cancers, which oncologists can use to inform their treatment decisions. In addition, all tests provide an estimate of tumor mutational burden that enables oncologists to predict immunotherapy response as well.
Key facts about Foundation Medicine
- Founded Year: 2010
- Location: Cambridge (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2017
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $96.5M
- Employee Count: 1,769 as on Jun 30, 2026
- Investors: Curie.Bio, Google Ventures and 11 Others
- Latest Funding Round: Series B, Jan 08, 2013, $*****
- Highlight: Acquired
5. Lunit
Developer of artificial intelligence solutions for cancer detection and treatment. The company’s technology supports early-stage cancer detection, enabling timely management and increased survival chances. It also provides artificial intelligence biomarkers for immunotherapy, predicting treatment response to increase efficacy. The company focuses on advancing precision oncology products.
Key facts about Lunit
- Founded Year: 2013
- Location: Seoul (South Korea)
- Stage: Public
- Total Funding till date: $135M
- Employee Count: 337 as on Jun 30, 2026
- Investors: Deep Learning, Tybourne Capital Management and 24 Others
- Latest Funding Round: Series C, Nov 25, 2021, $*****
- Highlight: Public
NSG Ventures' Year-on-Year Investment Trends
NSG Ventures has invested in 22 companies over the last 5 years, with an average of 1 new investment annually in the last 5 years. As of May 2026, it has made 1 investment in this year. Its most recent first time investment was in Protuoso.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 1 | 0 | 1 |
2025 | 0 | 0 | 0 |
2024 | 1 | 0 | 1 |
2023 | 0 | 0 | 0 |
2022 | 0 | 0 | 0 |
2021 | 2 | 0 | 2 |
NSG Ventures' Investments by Stage
NSG Ventures has made 2 investments in Series A stage with an average round size of $14.5M, 1 investment in Seed stage with an average round size of $9.5M and 1 investment in Series C stage with an average round size of $61M.Stage of entry | No. of Investments |
|---|---|
Series A | 2 |
Seed | 1 |
Series C | 1 |
Note: We have considered here, only first round of investments
NSG Ventures' Investments by Sector
NSG Ventures has a diverse portfolio, with companies operating in the Enterprise Applications, HealthTech, Artificial Intelligence - Industry Applications, Blockchain Technology and Enterprise Infrastructure. Notably, it has invested in 19 Tech companies, 17 Enterprise (B2B) companies, 8 Software companies and at least 4 companies focusing on Saas.Sector | No. of Investments |
|---|---|
Enterprise Applications | 2 |
HealthTech | 2 |
Artificial Intelligence - Industry Applications | 1 |
Blockchain Technology | 1 |
Enterprise Infrastructure | 1 |
Others | 3 |
Note: We have considered here, only first round of investments
NSG Ventures' Investments by Geography
NSG Ventures has made most investments in Singapore (1), followed by South Korea where it has made 1 investment.Country | No. of Investments |
|---|---|
Singapore | 1 |
South Korea | 1 |
United Arab Emirates | 1 |
United States | 1 |
Note: We have considered here, only first round of investments
NSG Ventures' recent investments
NSG Ventures has made 1 investments in 2026 so far - Protuoso.Here are the most recent investments by NSG Ventures:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
May 27, 2026 | United States | Seed | 8156 | [+2] | |
Jan 26, 2024 | Singapore | Series A | 7249 | [+2] | |
Nov 25, 2021 | South Korea | Series C | 7715 | [+3] | |
May 31, 2021 | United Arab Emirates | Series A | 1575 | [+12] |
IPOs and Publicly Listed companies in NSG Ventures' Portfolio
6 of NSG Ventures' portfolio companies have become public. Lunit got listed on the Korea Exchange (KRX), in Jul 2022 at marketcap of $241M and Nubank got listed on the New York Stock Exchange (NYSE) at marketcap of $41.5B.Here are NSG Ventures' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jul 21, 2022 | Nov 25, 2021 | Series C | 5032 | |
Dec 09, 2021 | - | - | 4059 | |
Sep 17, 2021 | - | - | 2554 | |
Sep 17, 2020 | - | - | 7198 | |
Jan 30, 2020 | - | - | 8319 |
Acquired companies in NSG Ventures' Portfolio
2 companies from NSG Ventures' portfolio have been acquired. The most recent acquisition was Lexent Bio in Jun 2020 by Foundation Medicine for $*****.Here are NSG Ventures' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jun 12, 2020 | - | - | 9398 | |
Jan 12, 2015 | - | - | 5760 |
Team profile of NSG Ventures
NSG Ventures has a team of 7 members including 1 Partner and 2 Venture Partners located in United States. NSG Ventures' team does not sit on the board of any company as of now.Here is a list of all team members in NSG Ventures:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | - | - | ||
Venture Partner | New York City | - | ||
Venture Partner | Oakland | - | - |
Co-investors of NSG Ventures
Over the past 5 years, 37 investors have co-invested in NSG Ventures's portfolio companies. This includes funds and angels.
- Invested before NSG Ventures: Legend Capital, IMM Investment and 12 others have invested in rounds before NSG Ventures. There is 1 company where Legend Capital has invested before NSG Ventures and 1 company where IMM Investment has invested before NSG Ventures.
- Top Co-investors of NSG Ventures: 23 investors entered a company along with NSG Ventures. These include investors like Health Quest Capital (1 company).
Recent News related to NSG Ventures
•
Protuoso Biosciences Raises $9.5M in Seed FundingFinSMEs•May 27, 2026•Darwin Ventures, Daya Group, Protuoso, NSG Ventures and 3 others
•
GDMC secures $28.1m capital from Series A fundingSingapore Business Review•Jan 25, 2024•GDMC, Celadon Partners, WI Harper Group, SEEDS Capital and 2 others
•
Morse Micro tops up Series B with another $30 million from super fundsStartup Daily•Nov 28, 2022•Morse Micro, TelstraSuper, HESTA, Hostplus and 4 others
•
Medical AI Provider Lunit Raises $61M in Funding Round Led By Major Global Healthcare InvestorsCNW•Nov 25, 2021•Lunit, Health Quest Capital, Casdin Capital, BrightEdge and 2 others
